Johnson & Johnson
JNJ: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|?m | LOCK|k& | LOCK|<^<Z&@w |
J&J Earnings: Raising Our Fair Value on New Launches, but Long-Term Guidance Looks Optimistic
Johnson & Johnson reported 9.9% sales growth and adjusted earnings per share down 2.5% in the first quarter. Management raised its 2026 growth guidance midpoints by 30 basis points to 7% on the top line and by 20 basis points to 5.7% for adjusted EPS. Shares were up 1% during April 14 trading.
